Corbus Pharmaceuticals (CRBP) vs Elicio Therapeutics (ELTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Elicio Therapeutics (ELTX) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, losing 82.8% versus a loss of 82.8%. Over five years, CRBP leads with a -92.2% price change compared with -96.1% for ELTX. Corbus Pharmaceuticals is the larger company by market cap ($42.4 million vs $41.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBP | ELTX |
|---|---|---|
| Share price | $2.06 | $1.45 |
| Market cap | $42.45M | $41.05M |
| 1-day change | -15.40% | -3.33% |
| YTD return | -74.69% | -81.78% |
| 1-year return | -82.85% | -82.84% |
| 5-year return | -92.23% | -96.13% |
| EPS (TTM) | $-6.04 | $-1.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-78.54M | $-39.57M |
| 52-week high | $12.88 | $16.00 |
| 52-week low | $2.01 | $1.25 |
| Distance from 52-week high | -84.01% | -90.94% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1551.94% | +842.76% |
| Average volume | 1.11M | 324.71K |
| Shares outstanding | 20.61M | 28.31M |
| Employees | 36 | 33 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Corbus Pharmaceuticals
CRBP stock →Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees
About Elicio Therapeutics
ELTX stock →Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
CRBP vs ELTX FAQ
Which is bigger, Corbus Pharmaceuticals or Elicio Therapeutics?
Corbus Pharmaceuticals (CRBP) is larger, with a market capitalization of $42.45M compared with $41.05M for Elicio Therapeutics (ELTX).
Which stock has performed better over the past year, CRBP or ELTX?
ELTX returned -82.84% over the past 12 months, compared with -82.85% for CRBP (price return, excluding dividends). Past performance does not predict future results.
Are Corbus Pharmaceuticals and Elicio Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.